clinical trial · NCT05514873
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB Biopharma SRL·phase3·completed·n = 26
Generalized Myasthenia Graviszilucoplan (RA101495)
brief summary
The purpose of the study is to evaluate the safety and tolerability of switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) Zilucoplan in study participants with generalized myasthenia gravis (gMG)
started
Oct 31, 2022
primary completion
Mar 13, 2024
completion
Oct 23, 2024
last updated
Sep 3, 2025
official title
A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol